New Skyrizi and Rinvoq data show disease control in inflammatory bowel disease
11th October 2026 – AbbVie announced the presentation of 22 scientific abstracts from its market-leading inflammatory bowel disease (IBD) portfolio at the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting in Nashville, Tennessee, Oct. 9-14.
Data presented will include newly unveiled AFFIRM results showing efficacy for SKYRIZI® (risankizumab-rzaa) in advanced therapy-naïve Crohn’s disease (CD) patients, open-label extension analyses demonstrating long-term outcomes with SKYRIZI in difficult-to-treat IBD and growing real-world evidence supporting RINVOQ® (upadacitinib) in advanced CD.
“People living with IBD want treatments that meaningfully reduce the burden of their disease,” said Ryan DeMasi, M.D., vice president, global medical affairs, immunology, AbbVie. “Our presence at ACG reflects AbbVie’s drive, as a leader in IBD, to provide what matters most to patients — therapies that perform over time and against the most complicated drivers of disease.”
The ACG conference agenda is available here.
Select AbbVie oral and poster presentations highlighted here.
- New Phase 3 AFFIRM data show higher rates of clinical and endoscopic response in Crohn’s disease patients treated with subcutaneous SKYRIZI versus placebo across all efficacy endpoints and observed subgroups
- New open-label extension analyses demonstrate sustained endoscopic outcomes over time with SKYRIZI, even in patients with complex disease characteristics and prior treatment exposure
- In real-world studies, patients with advanced Crohn’s disease achieved disease control with RINVOQ, highlighting its potential benefit for difficult-to-treat patients
- The breadth of scientific abstracts and oral presentations at the American College of Gastroenterology 2026 Annual Scientific Meeting demonstrates AbbVie’s pursuit to address the complexities of inflammatory bowel disease care.
About SKYRIZI® (risankizumab-rzaa)
SKYRIZI is an interleukin-23 (IL-23) inhibitor that blocks IL-23 by selectively binding to its p19 subunit. IL-23, a cytokine involved in inflammatory processes, is thought to be linked to a number of chronic immune-mediated diseases.i SKYRIZI is approved by the U.S. Food and Drug Administration (FDA) for the treatment of moderately to severely active ulcerative colitis, plaque psoriasis, psoriatic arthritis and Crohn’s disease.iOn April 27, 2026, AbbVie announced submission of an application to the FDA seeking approval of SKYRIZI® for subcutaneous induction for the treatment of adult patients with moderately to severely active CD.About RINVOQ® (upadacitinib)
Discovered and developed by AbbVie scientists, RINVOQ is a JAK inhibitor that is being studied in several immune-mediated inflammatory diseases. Based on enzymatic and cellular assays, RINVOQ demonstrated greater inhibitory potency for JAK-1 vs JAK-2, JAK-3 and TYK-2. The relevance of inhibition of specific JAK enzymes to therapeutic effectiveness and safety is not currently known.Upadacitinib is being studied in Phase 3 clinical trials for alopecia areata, hidradenitis suppurativa, Takayasu arteritis, systemic lupus erythematosus and vitiligo. The use of upadacitinib for these diseases is not FDA approved, and its safety and efficacy have not been established for these diseases.
